羟苯磺酸钙胶囊联合胰激肽原酶片治疗糖尿病视网膜病变患者的效果

Effects of Calcium dobesilate capsules combined with Pancreatic kininogenase tablets in treatment of patients with diabetic retinopathy

目的:观察羟苯磺酸钙胶囊联合胰激肽原酶片治疗糖尿病视网膜病变患者的效果。方法:选取2020年9月到2021年12月该院收治的90例糖尿病视网膜病变患者进行前瞻性研究,采用随机数字表法将其分为观察组和对照组各45例。对照组给予胰激肽原酶肠溶片治疗,观察组在对照组基础上联合羟苯磺酸钙胶囊治疗,比较两组临床疗效、治疗前后超敏C反应蛋白(hs-CRP)、血管内皮生长因子(VEGF)、胰岛素样生长因子-1(IGF-1)水平、血糖指标[空腹血糖(FBG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)]水平和不良反应发生率。结果:观察组治疗总有效率为93.33%(42/45),高于对照组的75.56%(34/45),差异有统计学意义(P<0.05);治疗后,两组hs-CRP、VEGF、IGF-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组FBG、2hPG、HbA1c水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:羟苯磺酸钙胶囊联合胰激肽原酶片治疗糖尿病视网膜病变患者可提高治疗总有效率,降低hs-CRP、VEGF、IGF-1水平和血糖指标水平,其效果优于单纯胰激肽原酶肠溶片治疗。

Objective:To observe effects of Calcium dobesilate capsules combined with Pancreatic kininogenase tablets in treatment of patients with diabetic retinopathy.Methods:A prospective study was conducted on 90 patients with diabetic retinopathy admitted to this hospital from September 2020 to December 2021.They were divided into observation group and control group by using the random number table method,45 cases in each.The control group was treated with Pancreatic kininogenase enteric-coated tablets,while the observation group was treated with Calcium dobesilate capsules on the basis of that of the control group.The clinical efficacy,the levels of high-sensitivity C-reactive protein(hsCRP),vascular endothelial growth factor(VEGF)and insulin-like growth factor(IGF-1),the levels of blood glucose indexes[fasting blood glucose(FBG),2h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 93.33%(42/45),which was higher than 75.56%(34/45)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of hs-CRP,VEGF and IGF-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of FBG,2hPG and HbA1c in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Calcium dobesilate capsules combined with Pancreatic kininogenase tablets can improve the total effective rate of treatment and reduce the levels of hs-CRP,VEGF,IGF-1 and blood glucose in the patients with diabetic retinopathy.Moreover,it is superior to single Pancreatic kininogenase enteric-coated tablets treatment.